AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial
AbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday. The new product is codenamed ABBV-466 and combines Skyrizi, an IL-23 ...
October 19, 2026 08:51 AM EDT R&DPharma AbbVie’s Skyrizi combo beats Skyrizi alone in mid-stage Crohn’s trial Elizabeth Cairns Senior biopharma journalist AbbVie’s Skyrizi-based combination therapy for inflammatory bowel disease worked better than Skyrizi alone in a mid-stage trial in Crohn’s disease, the company said Monday. The … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that